Insulinotropic and glucagonotropic effects of beta-lactoglobulin

The present invention pertains to a) beta-lactoglobulin or b) a nutritional composition comprising beta-lactoglobulin for use in preventing and/or treating a metabolic disorder and/or muscle atrophy. It also pertains to a method of preventing and/or treating a metabolic disorder and/or muscle atrophy in a subject. It furthermore pertains to use of a) beta-lactoglobulin or b) a nutritional composition comprising beta-lactoglobulin for increasing the level of insulin and/or glucagon in the blood of a subject and the present invention also pertains to a non-therapeutic use or method of a) beta-lactoglobulin or b) a nutritional composition comprising BLG. It also pertains to beta-lactoglobulin (BLG) for use in preventing and/or treating diabetes or prediabetes in a subject. It furthermore pertains to a nutritional composition for use in preventing and/or treating diabetes or prediabetes in a subject..

Medienart:

Patent

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Europäisches Patentamt - (2022) vom: 23. Juni Zur Gesamtaufnahme - year:2022

Sprache:

Englisch

Beteiligte Personen:

MOSE MAIKE [VerfasserIn]
RITTIG NIKOLAJ FIBIGER [VerfasserIn]
MØLLER NIELS [VerfasserIn]
MIKKELSEN ULLA RAMER [VerfasserIn]
FREDERIKSEN PERNILLE DORTHEA [VerfasserIn]
LAURIDSEN KASPER BØGELUND [VerfasserIn]
CHRISTENSEN BRITT [VerfasserIn]
MARKHOLM MIE [VerfasserIn]
NIELSEN SØREN BANG [VerfasserIn]
JÆGER TANJA CHRISTINE [VerfasserIn]
SMEDEGAARD STINE BECH [VerfasserIn]
HULMAN ADAM [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2022-06-23, Last update posted on www.tib.eu: 2024-02-26, Last updated: 2024-03-01

Patentnummer:

AU2020388118

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA015166430